Medicure Inc (TSXV:MPH) is a pharmaceutical company focused on the development and commercialization of cardiovascular medicines for the U.S. market. Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives. We take pride in providing safe, efficacious, and cost-effective cardiovascular medicines that benefit both patients and healthcare providers.

Currently, we focus on the marketing & distribution of:
1. AGGRASTAT® (tirofiban hydrochloride) injections, a hospital-based product used in the cardiac catheterization lab. AGGRASTAT is the #1 used medication of its class in the U.S.
2. ZYPITAMAG® (pitavastatin) tablets, the latest statin medication approved by the FDA in 2017.

In 2020, we acquired Marley Drug, a local pharmacy in North Carolina. Our acquisition of Marley Drug increases patient access to medications, including Medicure's primary care drug, ZYPITAMAG® (Pitavastatin) tablets.

At Medicure, our passion drives us to innovate and find solutions to better support patients.

For more information, please see our website at www.medicure.com and follow us on Twitter at @MedicureInc. For guidelines on engaging with Medicure on social media, please visit bit.ly/MedicureSocial

Pharmaceutical

Medicure

Medicure's headquarters in Winnipeg, Canada

Albert D. Friesen

Neil Owens

Jeannette Rosado (Gina)

Guido Pinares Chirinos

Mohamed Ghoniem

Haaris Uddin

Scott Dyck

Sales and Marketing

Medicure

Org chart

Teams

Sales and Marketing

Offices

Similar companies